Failure of protein quality control in amyotrophic lateral sclerosis - PubMed (original) (raw)
Review
. 2006 Nov-Dec;1762(11-12):1038-50.
doi: 10.1016/j.bbadis.2006.06.006. Epub 2006 Jun 18.
Affiliations
- PMID: 16876390
- DOI: 10.1016/j.bbadis.2006.06.006
Free article
Review
Failure of protein quality control in amyotrophic lateral sclerosis
Edor Kabashi et al. Biochim Biophys Acta. 2006 Nov-Dec.
Free article
Abstract
The protein chaperoning and ubiquitin-proteasome systems perform many homeostatic functions within cells involving protein folding, transport and degradation. Of paramount importance is ridding cells of mutant or post-translationally modified proteins that otherwise tend to aggregate into insoluble complexes and form inclusions. Such inclusions are characteristic of many neurodegenerative diseases and implicate protein misfolding and aggregation as common aspects of pathogenesis. In the most common familial form of ALS, mutations in SOD1 promote misfolding of the protein and target it for degradation by proteasomes. Although proteasomes can degrade the mutant proteins efficiently, altered solubility and aggregation of mutant SOD1 are features of the disease and occur most prominently in the most vulnerable cells and tissues. Indeed, lumbar spinal cord of mutant SOD1 transgenic mice show early reduction in their capacity for protein chaperoning and proteasome-mediated hydrolysis of substrates, and motor neurons are particularly vulnerable to aggregation of mutant SOD1. A high threshold for upregulating key pathways in response to the stress of added substrate load may contribute to this vulnerability. The broad spectrum neuroprotective capability and efficacy of some chaperone-based therapies in preclinical models makes these pathways attractive as targets for therapy in ALS, as well as other neurodegenerative diseases. A better understanding of the mechanisms governing the regulation of protein chaperones and UPS components would facilitate development of treatments that upregulate these pathways in a coordinated manner in neural tissue without long term toxicity.
Similar articles
- Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues.
Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, Rothstein JD. Watanabe M, et al. Neurobiol Dis. 2001 Dec;8(6):933-41. doi: 10.1006/nbdi.2001.0443. Neurobiol Dis. 2001. PMID: 11741389 - Inducible superoxide dismutase 1 aggregation in transgenic amyotrophic lateral sclerosis mouse fibroblasts.
Turner BJ, Lopes EC, Cheema SS. Turner BJ, et al. J Cell Biochem. 2004 Apr 1;91(5):1074-84. doi: 10.1002/jcb.10782. J Cell Biochem. 2004. PMID: 15034941 - Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1.
Niwa J, Yamada S, Ishigaki S, Sone J, Takahashi M, Katsuno M, Tanaka F, Doyu M, Sobue G. Niwa J, et al. J Biol Chem. 2007 Sep 21;282(38):28087-95. doi: 10.1074/jbc.M704465200. Epub 2007 Jul 31. J Biol Chem. 2007. PMID: 17666395 - Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease.
Tu PH, Gurney ME, Julien JP, Lee VM, Trojanowski JQ. Tu PH, et al. Lab Invest. 1997 Apr;76(4):441-56. Lab Invest. 1997. PMID: 9111507 Review. - Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response.
Bendotti C, Marino M, Cheroni C, Fontana E, Crippa V, Poletti A, De Biasi S. Bendotti C, et al. Prog Neurobiol. 2012 May;97(2):101-26. doi: 10.1016/j.pneurobio.2011.10.001. Epub 2011 Oct 20. Prog Neurobiol. 2012. PMID: 22033150 Review.
Cited by
- Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction.
Kikuchi K, Kawahara KI, Uchikado H, Miyagi N, Kuramoto T, Miyagi T, Morimoto Y, Ito T, Tancharoen S, Miura N, Takenouchi K, Oyama Y, Shrestha B, Matsuda F, Yoshida Y, Arimura S, Mera K, Tada KI, Yoshinaga N, Maenosono R, Ohno Y, Hashiguchi T, Maruyama I, Shigemori M. Kikuchi K, et al. Exp Ther Med. 2011 Sep;2(5):771-775. doi: 10.3892/etm.2011.281. Epub 2011 Jun 7. Exp Ther Med. 2011. PMID: 22977573 Free PMC article. - Spinal cord trauma and the molecular point of no return.
Yip PK, Malaspina A. Yip PK, et al. Mol Neurodegener. 2012 Feb 8;7:6. doi: 10.1186/1750-1326-7-6. Mol Neurodegener. 2012. PMID: 22315999 Free PMC article. Review. - An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons.
Boselli M, Lee BH, Robert J, Prado MA, Min SW, Cheng C, Silva MC, Seong C, Elsasser S, Hatle KM, Gahman TC, Gygi SP, Haggarty SJ, Gan L, King RW, Finley D. Boselli M, et al. J Biol Chem. 2017 Nov 24;292(47):19209-19225. doi: 10.1074/jbc.M117.815126. Epub 2017 Sep 26. J Biol Chem. 2017. PMID: 28972160 Free PMC article. - The genetics of amyotrophic lateral sclerosis: current insights.
Alsultan AA, Waller R, Heath PR, Kirby J. Alsultan AA, et al. Degener Neurol Neuromuscul Dis. 2016 May 13;6:49-64. doi: 10.2147/DNND.S84956. eCollection 2016. Degener Neurol Neuromuscul Dis. 2016. PMID: 30050368 Free PMC article. Review. - A role for ubiquilin 2 mutations in neurodegeneration.
Daoud H, Rouleau GA. Daoud H, et al. Nat Rev Neurol. 2011 Oct 11;7(11):599-600. doi: 10.1038/nrneurol.2011.163. Nat Rev Neurol. 2011. PMID: 21989241 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous